Recce Pharmaceuticals Ltd (ASX: RCE) Share Price and News

Mr Graham is the Chief Executive Officer of Recce Pharmaceuticals. He brings extensive experience in marketing, business development, and the commercialisation of early-stage technologies with global potential. With a proven track record of growing globally focused companies, he has applied his expertise to Recce, including serving on its Board of Directors. He has participated in nearly every capital raise to date, demonstrating a strong commitment to expanding Recces commercial opportunities and clinical programs.

Mr McKeough is an experienced executive and solicitor. Before being appointed as a non-executive director on 1 September 2022, he served as Recces company secretary and he has been involved with the company since 2017. He, who is a practising solicitor, has extensive experience serving as a director in many sectors, including for companies involved in professional services, corporate services, regulatory technology, sports technology, charities, health, biotech, child care and education.

Dr Dunton has held leadership positions at various biotechnology and pharmaceutical companies including serving as president and chief executive officer at Panacos Pharmaceuticals, Inc., Metaphore Pharmaceuticals, Inc., and chief operating officer at Emisphere Technologies, Inc. Dr Dunton served in several positions at Johnson and Johnson including president and managing director at the Janssen Research Foundation where he was responsible for leading over 2,000 professionals worldwide and prior to this as vice president of global clinical research and development at the R.W. Johnson Pharmaceutical Research Institute. During his career, he has been responsible for the approval of 20 New Drug Applications, an amalgamation of prescription and OTC products.

Ms Dilizia is a Qualified Medical Scientist with specialisation in medical microbiology. Previously, she had a executive career in public relations and marketing across retail, industrial, service and education sectors. She was a market research consultant, which included marketing development of health-care and pharmaceutical products.

Dr. Prendergast is Non-Executive Chairman and Co-Founder of Palatin Technologies developing targeted therapeutics for the treatment of diseases with significant unmet medical need and Executive Chairman of Angis Bio, a privately held company focused on developing new small format protein drug conjugates for cancer. He was previously Lead Director of Nighthawk Biosciences, Inc., a publicly traded, clinical stage immunomodulatory company, a cofounder and member of the board of the life science companies, Avigen, AVAX Technologies, MediciNova Inc and a member of the Advisory Board for the Institute for the Biotechnology of Infectious Diseases (IBID) at the University of Technology Sydney, now called the ithree Institute. Prior to that he was a Managing Director of The Castle Group Ltd., a New York medical venture capital firm. During his career, he has been responsible for the approval of three (3) New Drug Applications.

Dr Ward is a qualified chemist with specialisation in pharmaceutical quality management and product development. Before Recce Pharmaceuticals, he held a technical speciality and special project leadership role with Pfizer Pharmaceuticals, involving providing data for the regulatory submissions to the FDA and TGA. After Pfizer, he was the Laboratory Manager for Solbec, involving, again as presently, drug specifications and pharmaceutical trials for the ASX-Listed company. He was Quality Manager at Phebra and responsible for product quality, product introduction and release of all drugs of the company with the TGA.

-

-

-

-